Personal tools

Sponsorname

Your company could advertise here

www.fla-consulting.eu

Document:EU EMEA/CHMP/313666/2005 - GUIDELINE ON THE EXPOSURE TO MEDICINAL PRODUCTS DURING PREGNANCY: NEED FOR POST-AUTHORISATION DATA 14-Nov-2005: Difference between revisions

From GxPlex

Jump to: navigation, search
↠Older edit
Migrate to Template:DocumentData for PageForms (GxPlexBot)
Remove static References table, superseded by live #ask in Template:DocumentData (GxPlexBot)
 
Line 26: Line 26:
|contributors=
|contributors=
}}
}}
<noinclude>
== References ==
{| class="wikitable"
! Reference !! Scope !! Document part !! Language !! Preview
|-
| [[Reference:EU EMEA/CHMP/313666/2005 - GUIDELINE ON THE EXPOSURE TO MEDICINAL PRODUCTS DURING PREGNANCY: NEED FOR POST-AUTHORISATION DATA 14-Nov-2005 2.1]] || HM || 2.1 || EN || 2.1 Background The majority of medicinal products or chemical substances administered to a pregnant woman could have effects on the foetus either before the placenta is fully developed or ...
|}
</noinclude>

Latest revision as of 14:15, 16 July 2026


Document information
Reference EU EMEA/CHMP/313666/2005

- GUIDELINE ON THE EXPOSURE TO MEDICINAL PRODUCTS DURING PREGNANCY: NEED FOR POST-AUTHORISATION DATA 14-Nov-2005

Validity area EU
Scope(s) HM
Document name EMEA/CHMP/313666/2005

- GUIDELINE ON THE EXPOSURE TO MEDICINAL PRODUCTS DURING PREGNANCY: NEED FOR POST-AUTHORISATION DATA

Version / Revision 14-Nov-2005
Status Current
Document type Official guideline
Language(s) EN
Description EMEA/CHMP/313666/2005

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

GUIDELINE ON THE EXPOSURE TO MEDICINAL PRODUCTS DURING PREGNANCY: NEED FOR POST-AUTHORISATION DATA

Official source Official link
Restricted access No
Submitted by Florian Adragna
Contributors

References

 ScopeDocument partLanguagePreview
EU EMEA/CHMP/313666/2005 - GUIDELINE ON THE EXPOSURE TO MEDICINAL PRODUCTS DURING PREGNANCY: NEED FOR POST-AUTHORISATION DATA 14-Nov-2005 2.1HM2.1EN2.1 Background The majority of medicinal products or chemical substances administered to a pregnant woman could have effects on the foetus either befo…
Retrieved from "https://gxplex.org/index.php?title=Document:EU_EMEA/CHMP/313666/2005_-_GUIDELINE_ON_THE_EXPOSURE_TO_MEDICINAL_PRODUCTS_DURING_PREGNANCY:_NEED_FOR_POST-AUTHORISATION_DATA_14-Nov-2005&oldid=20332"